The PP pharmaceutical cannabis report

The PP pharmaceutical cannabis report

Since 2020, Prohibition Partners has managed to release a detailed report about pharmaceutical cannabis in rather short amounts of time, the second edition of the Pharmaceutical Cannabis Report being published in 2021 and being shortly followed by the third and most recent one last year. After approximately two years with a lot of interesting developments in the pharmaceutical area and beyond, we’re really excited to see how things unfolded and to compare the outcomes with the projected developments formulated by the prestigious cannabis institution.

A Short Summary

The 3rd Edition of The Pharmaceutical Cannabis Report provides a comprehensive overview of the global pharmaceutical cannabis industry, detailing the current state of clinical trials, patents, innovations, market sizing, and mergers and acquisitions (M&A) activities.

The report emphasizes that the integration of cannabis and cannabinoids into standardized modern medicine is still in its early stages worldwide. Despite this, a few cannabinoid products have been approved for treating limited conditions, although off-label use is widespread. A significant challenge in this field is completing the rigorous stages of clinical trials and establishing intellectual property (IP) around cannabinoid treatments, which has hindered new research and development.

2nd Edition vs. 3rd Edition

The 3rd Edition of The Pharmaceutical Cannabis Report focuses on the ongoing integration of cannabis and cannabinoids into standardized modern medicine. It highlights the early stages of this process globally and discusses the challenges of completing clinical trials and establishing intellectual property (IP) around cannabinoid treatments. The report provides detailed insights into clinical trials, patents, innovations, market sizing, and mergers and acquisitions (M&A) activities.

In contrast, the 2nd Edition of the report discusses the major opportunities and challenges in the medical cannabis space, emphasizing the evolving regulatory landscape. It covers the use of cannabinoids in treating medical conditions, the increasing importance of the endocannabinoid system in new therapeutics, and the difficulties faced by companies in navigating changing regulations.

The 3rd Edition notes that pain management is the most prevalent focus in clinical trials involving cannabinoids since 2010. It emphasizes recent activity around CBD as a treatment, while historically, combinations of THC and CBD have been more common. The report highlights that patented compounds like Sativex and Epidiolex dominate completed phase 3 trials and mentions a growing interest in targeting the endocannabinoid system.

The 2nd Edition also covers trends in clinical trials, noting at least 30 late-stage clinical trials using cannabinoid therapeutics that could significantly impact the medical cannabis space. It discusses the development of new routes of administration, such as metered inhalers and transdermal products, and the early research into minor cannabinoids like Cannabigerol (CBG) and Cannabichromene (CBC).

The 3rd Edition identifies Jazz Pharmaceuticals as the dominant player in the pharmaceutical cannabis industry, with a significant patent portfolio focused on CBD and THC, as well as related compounds like CBDV, THCV, and CBDA. The report outlines the most common conditions addressed in patents, including epilepsy, cancer, seizures, and autism spectrum disorder.

Similarly, the 2nd Edition discusses the current trends in cannabis patents and the importance of patenting activity in the industry. It highlights the challenges and opportunities of managing intellectual property and the potential for generic cannabinoid opportunities.

The 3rd Edition highlights technological advancements in the pharmaceutical cannabis value chain, including the use of AI and robotics for optimizing cultivation, the development of micropropagation techniques, and the use of F1 hybrid seeds. It also mentions new delivery formats and cannabinoid formulations targeting specific ailments.

The 2nd Edition also focuses on innovation, discussing the rise of synthetic cannabinoids and their potential benefits, such as reduced costs and environmental impact. It explores the current state of the synthetic cannabinoids market and the potential for new therapeutic applications of minor cannabinoids and novel formulations.

The 3rd Edition reports significant transactions in the pharmaceutical cannabis industry over the past three years, including billion-dollar acquisitions by Jazz Pharmaceuticals and Pfizer. It highlights consolidation within the German and Austrian markets and strategic acquisitions in the US and Canada aimed at expanding patent portfolios and product pipelines.

The 2nd Edition provides a detailed case study on GW Pharmaceuticals, discussing its challenges and successes in the pharmaceutical cannabis space. It emphasizes the importance of strategic M&A activities in shaping the industry's future and the role of large pharmaceutical companies in driving growth.

The 3rd Edition estimates global sales within the pharmaceutical cannabis industry to reach approximately USD 1.11 billion in 2023, with growth projected to USD 1.37 billion by 2027. It identifies Epidiolex as the dominant product, with an estimated market share of around 76% in 2023, and notes that most sales are concentrated in the United States and Europe.

The 2nd Edition discusses the market potential for medical cannabinoids and the gradual shift from unapproved products like smoked flower and full-spectrum oils to more precise pharmaceutical formulations. It projects a trend towards the liberalization of adult-use cannabis, which will further differentiate medical products from recreational use.

Both editions of The Pharmaceutical Cannabis Report provide valuable insights into the rapidly evolving pharmaceutical cannabis industry. The 3rd Edition offers updated information on clinical trials, patents, innovations, market sizing, and M&A activities, emphasizing the integration of cannabis into modern medicine and the challenges of regulatory compliance. The 2nd Edition provides a broader overview of the industry's opportunities and challenges, focusing on the endocannabinoid system, synthetic cannabinoids, and the potential for new therapeutic applications. Together, these reports offer a comprehensive understanding of the current dynamics and future prospects of the pharmaceutical cannabis market.

Patented and Unpatented Compounds

In the pharmaceutical cannabis industry, patented compounds represent significant milestones, indicating a high level of research and development that ensures exclusivity in production and distribution. These patents protect the intellectual property of companies, granting them the exclusive right to produce and sell specific formulations for a period, typically up to 20 years. This protection encourages innovation by allowing companies to recoup their investment in research and development. The compounds detailed in the 3rd and 2nd Editions of The Pharmaceutical Cannabis Report highlight the advancements in this field, showcasing both patented giants like Epidiolex and Sativex, and emerging minor cannabinoids such as CBDV and THCV.

Both editions of The Pharmaceutical Cannabis Report provide detailed insights into key compounds driving the pharmaceutical cannabis industry. The 3rd Edition offers a more detailed look at emerging minor cannabinoids and highlights the increasing importance of synthetic cannabinoids. The 2nd Edition provides a broader overview of the industry's foundational compounds and the early stages of synthetic cannabinoid development. Together, these reports highlight the dynamic and evolving nature of the pharmaceutical cannabis market, driven by both well-established and emerging cannabinoid compounds.

These two reports represent a vital tool for anyone either interested or already involved in the cannabis industry, providing comprehensive insights into trends, innovations, and regulatory changes for business leaders, investors, and policymakers alike. Available packages include the Report with Market Sizing Analysis for £1499, the Report plus a 2-Hour Analyst Consultation for £2399, the Clinical Trials Database for £749, the Patent Portfolio for £699, and the comprehensive package with all features for £3299.

Written by DANIEL CIUREA

Source:

Share



Hortibiz Newsradio
Tune in!

Hortibiz Newsradio

24/7 news and information

Stay up to date with Hortibiz Daily News.
Subscribe to Hortibiz Daily News!

Stay up to date with Hortibiz Daily News.

Horticultural news, market insights and technology

Career at Holland Hortimedia?
Apply!

Career at
Holland Hortimedia?

Content manager m/f – Sales manager m/f

Ads from tuinbouwmarktplaats.nl

Today on Hortibiz Newsradio, listen back to podcasts!